local_hospital

Vita Longa Sp. z o.o.

Address
lock Available on a paid plan

Gastroenterology and Inflammatory Bowel Disease

At Vita Longa Sp. z o.o. in Katowice, a major share of research focuses on digestive system diseases, especially ulcerative colitis and Crohn’s disease. These studies are designed to assess new treatment options, improve disease control, and better define how remission can be achieved and maintained.

  • Clinical research in ulcerative colitis aims to evaluate new therapies for inducing and maintaining remission.
  • Studies in Crohn’s disease explore whether novel treatments can improve bowel healing and symptom control.
  • Several trials assess the effectiveness and safety of approaches for inflammatory bowel disease.

This area reflects a strong clinical interest in advancing care for chronic intestinal inflammation and improving outcomes for patients with complex gastrointestinal conditions.

Heart Failure and Cardiovascular Research

The site also contributes to cardiovascular diseases research, with trials in heart failure, hypertension, and broader cardiovascular risk reduction. The main goal is to test whether new therapies can lower complications and support better long-term heart health.

  • Research in heart failure examines treatment strategies for patients with reduced or preserved ejection fraction.
  • Trials in type 2 diabetes and cardiovascular risk study ways to prevent heart-related events.
  • Some studies focus on inflammation-linked heart disease and the prevention of worsening cardiac outcomes.

This portfolio shows an active interest in improving treatment effectiveness for people living with chronic cardiac conditions.

Skin, Allergy, and Immune-Mediated Conditions

Another prominent area at this hospital/clinic is research into skin and connective tissue diseases and immune system diseases, including acne vulgaris, psoriasis, atopic dermatitis, chronic spontaneous urticaria, and allergic rhinoconjunctivitis. These trials are focused on testing new treatments and improving symptom relief for conditions that often affect daily quality of life.

  • Studies in psoriasis and atopic dermatitis evaluate whether new therapies can better control skin inflammation.
  • Research in acne vulgaris looks at long-term safety and effectiveness of topical treatment options.
  • Allergy-related trials aim to reduce birch pollen-induced rhinoconjunctivitis symptoms and medication use.

These projects highlight a broad effort to improve care for immune-driven skin and allergy disorders through more effective and better-tolerated treatments.

Neurology, Pain, and Metabolic Disorders

The research program also covers nervous system diseases, musculoskeletal diseases, and nutritional and metabolic diseases. Key studies involve migraine, chronic low back pain, diabetic neuropathic pain, gastroparesis, and obesity, with a clear emphasis on evaluating therapies that may ease symptoms and improve everyday functioning.

  • Trials in migraine investigate both prevention and acute symptom relief.
  • Studies in chronic non-specific low back pain and neuropathic pain assess new options for pain reduction.
  • Research on gastroparesis and obesity explores whether emerging treatments can improve digestive symptoms and metabolic health.

This mix of studies shows a practical focus on conditions that can significantly affect comfort, mobility, and day-to-day wellbeing.

Women’s Health and Other Specialized Studies

Vita Longa Sp. z o.o. also participates in research on female urogenital diseases and pregnancy complications, including endometriosis-related pain and oral contraception. In addition, some trials address rheumatoid arthritis and systemic lupus erythematosus, reflecting a wider interest in chronic inflammatory diseases.

  • Women’s health studies examine new approaches for endometriosis pain and contraceptive-related outcomes.
  • Autoimmune disease trials evaluate potential therapies for rheumatoid arthritis and systemic lupus erythematosus.
  • These studies aim to improve treatment effectiveness while also monitoring safety and tolerability.

The site’s portfolio combines targeted specialty care with broader clinical research in chronic, immune-mediated, and symptom-driven conditions.

Site Overview

assignment
59
connected trials
corporate_fare
43
sponsors
science
82
IMPs

Activity Indicator

Last 6 months

7
Trials started
-36% vs previous period.
11
Trials started 6–12 months ago
59
Total trials linked
Highly Active
trending_downDeclining-36%
3
1
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 13 therapeutic areas and 15 of 82 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 81 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
26
Sponsors (total)
43
Active sponsors
22

Sponsor Network

Top 22 by active trials.

lock +21 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +12 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
59
Outperforms 96% of sites
public
Therapeutic diversity
13areas
Outperforms 97% of sites
groups
Sponsor diversity
43sponsors
Outperforms 98% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Vita Longa Sp. z o.o.

lock Showing 1 of 59 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)Remegen Co. Ltd.Phase IIINot Yet RecruitingNov 2022Jan 2025

IMP list

lock Showing 1 of 82 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Duvakitug4Unknown2026-03-022026-07-22

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.